GuidelineMMWR. Morbidity and mortality weekly report2023
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Guideline in MMWR. Morbidity and mortality weekly report, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 4 syntheses or guidelines pooled it, 317 citations in OpenAlex.
- RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.Human vaccines & immunotherapeutics · 2026Pooled it
- Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2024.MMWR. Morbidity and mortality weekly report · 2024Guideline
- Respiratory syncytial virus disease morbidity in Australian infants aged 0 to 6 months: a systematic review with narrative synthesis.BMC public health · 2023Pooled it
- Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.MMWR. Morbidity and mortality weekly report · 2023Guideline
- Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.Pediatrics · 2026Trial
- Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months.Human vaccines & immunotherapeutics · 2025Trial
- Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150.The Journal of infectious diseases · 2025Trial
- The probability of reducing hospitalization rates for bronchiolitis with epinephrine and dexamethasone: A Bayesian analysis.PloS one · 2025Trial
- Expenditures attributable to infant lower respiratory tract infection due to respiratory syncytial virus in the US: A real-world study using the PharMetrics Plus Database, 2015-2023.Human vaccines & immunotherapeutics · 2026Article
- Clinical characteristics and outcomes of respiratory syncytial virus and human metapneumovirus ınfections in children under five years of age.European journal of pediatrics · 2026Article
- Racial and Ethnic Differences in the Association Between Maternal RSV Awareness and Vaccine Uptake.Journal of racial and ethnic health disparities · 2026Article
- Article
- Respiratory Pathogen Co-Detection in Hospitalized Infants with Bronchiolitis and Implementation of Universal Nirsevimab Immunoprophylaxis: A Six-Year Observational Study.Children (Basel, Switzerland) · 2026Article
- Article
- Sociodemographic and Clinical Factors Associated With Nirsevimab Receipt Among Children Aged Younger Than 20 Months in the New Vaccine Surveillance Network in 2023 to 2025.Hospital pediatrics · 2026Article
- Long-acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention.Pediatric investigation · 2026Article
- CAUSAL-RSV: A study protocol for a causal mediation analysis of RSV vaccine effects in infants using real-world data.medRxiv : the preprint server for health sciences · 2026Article
- Maternal Immunization Against Respiratory Syncytial Virus: An Integrative Review of Efficacy, Safety, and Implementation.Vaccines · 2026Review
- Burden of respiratory syncytial virus in spinal muscular atrophy: a retrospective nationwide cross-sectional and birth cohort study.Orphanet journal of rare diseases · 2026Article
- Respiratory Syncytial Virus Immunization Intention During Pregnancy and Infancy.JAMA network open · 2026Article
121 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection among infants and young children. Since October 2021, the Advisory Committee on Immunization Practices (ACIP) Maternal and Pediatric RSV Work Group has reviewed evidence on the safety and efficacy of nirsevimab among infants and young children. On August 3, 2023, ACIP recommended nirsevimab for all infants aged <8 months who are born during or entering their first RSV season and for infants and children aged 8-19 months who are at increased risk for severe RSV disease and are entering their second RSV season. On the basis of pre-COVID-19 pandemic patterns, nirsevimab could be administered in most of the continental United States from October through the end of March. Nirsevimab can prevent severe RSV disease among infants and young children at increased risk for severe RSV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.